Ascendis Pharma A (ASND) Receivables (2012 - 2026)

Ascendis Pharma A has disclosed Receivables across 15 years of filings, most recently posting $209.2 million for Q1 2026.

• Receivables for Q1 2026 came in at $209.2 million, up 198.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $209.2 million (up 198.22% YoY), and the FY2025 annual result was $181.5 million, down 3.32% from the prior year.
• Receivables came in at $209.2 million for Q1 2026 at Ascendis Pharma A, up from $181.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $209.2 million in Q1 2026 to a low of $4.7 million in Q2 2022.
• The 5-year median for Receivables is $44.6 million (2024), against an average of $72.7 million.
• Across the five-year window, Receivables jumped 8906.72% in 2022 and slipped 3.32% in 2025, its largest moves.
• Ascendis Pharma A's Receivables stood at $25.2 million in 2022, then surged by 134.3% to $59.1 million in 2023, then soared by 217.38% to $187.7 million in 2024, then fell by 3.32% to $181.5 million in 2025, then rose by 15.26% to $209.2 million in 2026.
• The last three Receivables figures came in at $209.2 million (Q1 2026), $181.5 million (Q4 2025), and $157.5 million (Q3 2025), per Business Quant data.